Searchable abstracts of presentations at key conferences in endocrinology

ea0078oc4.6 | Oral Communications 4 | BSPED2021

The management of adrenal cell carcinoma in the United Kingdom at a single centre: a 25 year experience

Goff Nicole , Hughes Claire , Katugampola Harshini , Musthaq Imran , Hindmarsh Peter , Peters Catherine , Brain Caroline , Jorgensen Mette , Dattani Mehul

Background: Adrenal cortical carcinoma (ACC) in children is a rare and aggressive disease. Further characterisation of the presenting features and biochemical markers are needed to support earlier diagnosis. Refractory hypertension related to high cortisol concentrations at presentation, and post-operative decrease in cortisol can be challenging to manage. Focus on endocrine management has not been previously described.Case Series: 34 patients (age 2 wee...

ea0051p038 | Pituitary and growth | BSPED2017

Growth hormone neurosecretory dysfunction as part of the spectrum of growth hormone deficiency disorders which benefit from growth hormone treatment

Caiulo Silvana , Gan Hoong-Wei , Hughes Claire R. , Amin Rakesh , Spoudeas Helen , Peters Catherine , Hindmarsh Peter , Shah Pratik , Dattani Mehul

Objectives: Current provocative tests for GH deficiency (GHD) are neither 100% sensitive nor specific. GH neurosecretory dysfunction (NSD) refers to the presence of growth failure, normal stimulated GH responses, but impaired spontaneous GH secretion. We describe our experience in managing GHNSD over 7 years.Methods: We retrospectively reviewed a cohort of 106 children admitted for 12-h overnight GH profiles (with 20-min sampling) between 2010 and 2016. ...

ea0050p318 | Obesity and Metabolism | SFEBES2017

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism and inflammation in human liver

Nikolaou Nikolaos , Gathercole Laura , Althari Sara , Green Charlotte , McNeil Catriona , Hughes Beverly , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. Steroid hormones and bile acids are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. We hypothesized that AKR1D1 plays a key role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 ...

ea0050p318 | Obesity and Metabolism | SFEBES2017

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism and inflammation in human liver

Nikolaou Nikolaos , Gathercole Laura , Althari Sara , Green Charlotte , McNeil Catriona , Hughes Beverly , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. Steroid hormones and bile acids are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. We hypothesized that AKR1D1 plays a key role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 ...

ea0085oc5.2 | Oral Communications 5 | BSPED2022

Central Delayed Puberty in Adolescence: Differentiating the phenotypes of Congenital Hypogonadotropic Hypogonadism and Self-Limited Delayed Puberty

Kokotsis Vasilis , Burchett Caroline , Butler Gary , Dattani Mehul , Hughes Claire , McGuigan Michael , Shah Pratik , Willemsen Ruben , Howard Sasha

Congenital hypogonadotropic hypogonadism (CHH) is a pathological condition characterised by lack of pubertal onset and must be differentiated from self-limited delayed puberty (SLDP). There is a significant overlap between these two conditions both in clinical and biochemical features, with current diagnostic approaches lacking sensitivity. Thus, paediatric endocrine clinicians are faced with difficulty in ascertaining the correct diagnosis in adolescence. The presence of cert...

ea0065p412 | Thyroid | SFEBES2019

Health utility of people with treatment-resistant hypothyroidism as measured with the EQ-5D-5L quality of life questionnaire

Hughes Dyfrig , Townson Julia , Owen-Jones Eleri , Playle Rebecca , Khan Inamullah , Kochhar Rupinder , Naseem Asma , Heald Adrian

Background: Primary hypothyroidism affects about 3% of the general population (5.1% women and 0.9% men). The majority of people are treated adequately with levothyroxine. However about 5–10% of hypothyroid patients (representing between 75 000 and 150 000 adults in the UK) continue to experience profound and sometimes disabling symptoms, such as fatigue/depression/impaired cognition, in spite of being adequately replaced biochemically. Before any trial of alternatives to ...

ea0063p41 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Prevalence and prognosis of bone metastases in pancreatic and small intestinal neuroendocrine tumours

Mammadov Emin , Hughes Nicola , Alnuaimi Asma , Chin Jun Liong , O'Toole Dermot , O 'Shea Donal , Heffernan Eric , Crowley Rachel K

Background: Neuroendocrine tumours (NET) can affect various tissues and organs, have different clinical presentation and prognosis, depending on the primary tumour site, grading, differentiation and functional status. Reported prevalence of bone metastases (BM) from NETs has been increasing with improved imaging modalities, reaching >40% in some reports. The BM diagnosis is associated with reduced overall survival; however, this was not confirmed by all studies.<p clas...

ea0044p40 | Adrenal and Steroids | SFEBES2016

Steroid metabolomics for diagnosis of inborn steroidogenic disorders – bridging the gap between clinician and scientist through computational approaches

Baranowski Elizabeth , Bunte Kerstin , Shackleton Cedric , Taylor Angela , Hughes Beverley , Biehl Michael , Tino Peter , Guran Tulay , Arlt Wiebke

Background: The urinary steroid metabolome is considered the fingerprint of adrenal gland function. Novel methods using mass spectrometry profiling have seen the advent of a new era for metabolomics with powerful implications for both diagnostics and discovery. Its interpretation is difficult and performed by few specialists with the expertise to do so. This makes it a relatively inaccessible tool for the majority of Clinical Endocrinologists.Objective: ...

ea0041ep728 | Neuroendocrinology | ECE2016

Women with idiopathic intracranial hypertension have a distinct andro-metabolic signature compared to polycystic ovary syndrome and simple obesity

Kempegowda Punith , O'Reilly Michael , Hornby Catherine , Botfield Hannah , Taylor Angela , Hughes Beverley , Tomlinson Jeremy , Arlt Wiebke , Sinclair Alexandra

Context: Idiopathic intracranial hypertension (IIH) is characterised by elevated intracranial pressure and occurs predominantly in obese premenopausal women. Signs and symptoms of polycystic ovary syndrome (PCOS) often coexist in IIH. Here we compared the androgenic and metabolic phenotypes in IIH, PCOS and simple obesity.Patients and Methods: We studied 25 patients with IIH (mean age 34.4±9.2 years; mean BMI 37.8±5.2 kg/m2), in comp...

ea0038oc1.4 | Early Career Oral Communications | SFEBES2015

Adipose tissue-specific androgen generation fuels an adverse metabolic phenotype in patients with polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Gathercole Laura , Bujalska Iwona , Taylor Angela , Hughes Beverley , Dunn Warwick , Semple Robert , Tomlinson Jeremy , Arlt Wiebke

Insulin resistance and androgen excess are the cardinal features of polycystic ovary syndrome (PCOS). Severity of hyperandrogenism and metabolic dysfunction in PCOS are closely correlated, but underlying mechanisms remain poorly understood. Aldoketoreductase type 1C3 (AKR1C3) is a key source of adipose androgen generation, activating androstenedione to testosterone (T). We postulated that AKR1C3 plays a critical role linking androgen metabolism and metabolic ...